Adaptive Biotechnologies ADPT Stock-Based Comp
Stock-Based Comp at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's stock-based comp?
- Adaptive Biotechnologies (ADPT) reported stock-based comp of $11.93M in Q1 2026.
- How has Adaptive Biotechnologies's stock-based comp changed year-over-year?
- Adaptive Biotechnologies's stock-based comp decreased by 1.8% year-over-year, from $12.15M to $11.93M.
- What is the long-term trend for Adaptive Biotechnologies's stock-based comp?
- Over 4 years (2021 to 2025), Adaptive Biotechnologies's stock-based comp has grown at a 4.5% compound annual growth rate (CAGR), from $43.25M to $51.48M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.